| |
Although
the sequences of many therapeutically relevant genes have been patented
as isolated or purified sequences, a major advantage of Sangamos
unique technology is that it regulates endogenous cellular genes and
is consequently independent of such patents. We have been granted
a U.S. patent that includes claims covering the activation or repression
of any endogenous gene in any cell type using zinc finger DNA-binding
proteins.
|